41 results on '"Grobben, Marloes"'
Search Results
2. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity
- Author
-
van Leeuwen, Leanne P. M., Grobben, Marloes, GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L., van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A. S. H.
- Published
- 2023
- Full Text
- View/download PDF
3. A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
- Author
-
Brinkkemper, Mitch, Poniman, Meliawati, Siteur-van Rijnstra, Esther, Iddouch, Widad Ait, Bijl, Tom P.L., Guerra, Denise, Tejjani, Khadija, Grobben, Marloes, Bhoelan, Farien, Bemelman, Denzel, Kempers, Ronald, van Gils, Marit J., Sliepen, Kwinten, Stegmann, Toon, van der Velden, Yme U., and Sanders, Rogier W.
- Published
- 2024
- Full Text
- View/download PDF
4. A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns
- Author
-
Chumbe, Ana, Grobben, Marloes, Capella-Pujol, Joan, Koekkoek, Sylvie M., Zon, Ian, Slamanig, Stefan, Merat, Sabrina J., Beaumont, Tim, Sliepen, Kwinten, Schinkel, Janke, and van Gils, Marit J.
- Published
- 2024
- Full Text
- View/download PDF
5. Into the Dark Serum Proteome: Personalized Features of IgG1 and IgA1 Repertoires in Severe COVID-19 Patients
- Author
-
Bondt, Albert, Hoek, Max, Dingess, Kelly, Tamara, Sem, de Graaf, Bastiaan, Peng, Weiwei, den Boer, Maurits A., Damen, Mirjam, Zwart, Ceri, Barendregt, Arjan, van Rijswijck, Danique M.H., Schulte, Douwe, Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Völlmy, Franziska, Snijder, Joost, Fortini, Francesca, Papi, Alberto, Volta, Carlo Alberto, Campo, Gianluca, Contoli, Marco, van Gils, Marit J., Spadaro, Savino, Rizzo, Paola, and Heck, Albert J.R.
- Published
- 2024
- Full Text
- View/download PDF
6. Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides antibodies for the neonate
- Author
-
Zilver, Sanne J.M., de Groot, Christianne J.M., Grobben, Marloes, Remmelzwaal, Sharon, Burgers, Esmee, Velasco, Daniela Nunez, Juncker, Hannah G., van Keulen, Britt J., van Goudoever, Johannes B., de Leeuw, Robert A., van Gils, Marit J., Ris-Stalpers, Carrie, and van Leeuwen, Elisabeth
- Published
- 2023
- Full Text
- View/download PDF
7. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
- Author
-
Claireaux, Mathieu, Caniels, Tom G., de Gast, Marlon, Han, Julianna, Guerra, Denise, Kerster, Gius, van Schaik, Barbera D. C., Jongejan, Aldo, Schriek, Angela I., Grobben, Marloes, Brouwer, Philip J. M., van der Straten, Karlijn, Aldon, Yoann, Capella-Pujol, Joan, Snitselaar, Jonne L., Olijhoek, Wouter, Aartse, Aafke, Brinkkemper, Mitch, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Bijl, Tom P. L., Torres, Jonathan L., Copps, Jeffrey, Martin, Isabel Cuella, de Taeye, Steven W., de Bree, Godelieve J., Ward, Andrew B., Sliepen, Kwinten, van Kampen, Antoine H. C., Moerland, Perry D., Sanders, Rogier W., and van Gils, Marit J.
- Published
- 2022
- Full Text
- View/download PDF
8. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
- Author
-
van der Velden, Yme U., Grobben, Marloes, Caniels, Tom G., Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Rijnstra, Esther Siteur-van, Tejjani, Khadija, Guerra, Denise, Kempers, Ronald, Stegmann, Toon, van Gils, Marit J., and Sanders, Rogier W.
- Published
- 2022
- Full Text
- View/download PDF
9. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
- Author
-
Sulbaran, Guidenn, Maisonnasse, Pauline, Amen, Axelle, Effantin, Gregory, Guilligay, Delphine, Dereuddre-Bosquet, Nathalie, Burger, Judith A., Poniman, Meliawati, Grobben, Marloes, Buisson, Marlyse, Dergan Dylon, Sebastian, Naninck, Thibaut, Lemaître, Julien, Gros, Wesley, Gallouët, Anne-Sophie, Marlin, Romain, Bouillier, Camille, Contreras, Vanessa, Relouzat, Francis, Fenel, Daphna, Thepaut, Michel, Bally, Isabelle, Thielens, Nicole, Fieschi, Franck, Schoehn, Guy, van der Werf, Sylvie, van Gils, Marit J., Sanders, Rogier W., Poignard, Pascal, Le Grand, Roger, and Weissenhorn, Winfried
- Published
- 2022
- Full Text
- View/download PDF
10. Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.
- Author
-
van der Straten, Karlijn, Guerra, Denise, Kerster, Gius, Claireaux, Mathieu, Grobben, Marloes, Schriek, Angela I., Boyd, Anders, van Rijswijk, Jacqueline, Tejjani, Khadija, Eggink, Dirk, Beaumont, Tim, de Taeye, Steven W., de Bree, Godelieve J., Sanders, Rogier W., and van Gils, Marit J.
- Subjects
SARS-CoV-2 ,IMMUNOLOGIC memory ,COVID-19 ,IMMUNE response ,B cells ,ANTIBODY titer ,FC receptors - Abstract
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (FcγRIIa) and FcγRIIIa, and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with FcγRIIa and FcγRIIIa and the RBD-specific MBC responses exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants. Author summary: The SARS-CoV-2 virus, first identified in 2019, swiftly led to a global pandemic. Crucial for the protection against re-infections are sufficient levels of neutralizing antibodies in the blood. However, SARS-CoV-2 have evolved into antigenically distinct variants of concern (VOC) that escape protection by these neutralizing antibodies. In addition, the relatively rapid waning of serum antibody titers raises questions about the sustainability of protection. In this study, we investigated the ability of antibodies and memory B cells to recognize the emerging variants after primary SARS-CoV-2 infection with different variants of concern. Compared with neutralizing antibodies, antibodies that can mediate Fc-mediated effector functions as well as memory B cells were, in general, more cross-reactive to other variants, irrespectively of the variant causing the infection. However, we found variations in the level of immune responses depending on the infecting variant, indicating differences in the immunogenicity of SARS-CoV-2 VOC. These results highlight the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
- Author
-
Brouwer, Philip J.M., Antanasijevic, Aleksandar, Ronk, Adam J., Müller-Kräuter, Helena, Watanabe, Yasunori, Claireaux, Mathieu, Perrett, Hailee R., Bijl, Tom P.L., Grobben, Marloes, Umotoy, Jeffrey C., Schriek, Angela I., Burger, Judith A., Tejjani, Khadija, Lloyd, Nicole M., Steijaert, Thijs H., van Haaren, Marlies M., Sliepen, Kwinten, de Taeye, Steven W., van Gils, Marit J., Crispin, Max, Strecker, Thomas, Bukreyev, Alexander, Ward, Andrew B., and Sanders, Rogier W.
- Published
- 2022
- Full Text
- View/download PDF
12. Into the dark serum proteome: personalized features of IgG1 and IgA1 repertoires in severe COVID-19 patients
- Author
-
Biomolecular Mass Spectrometry and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Bondt, Albert, Hoek, Max, Dingess, Kelly, Tamara, Sem, de Graaf, Bastiaan, Peng, Weiwei, den Boer, Maurits A, Damen, Mirjam, Zwart, Ceri, Barendregt, Arjan, van Rijswijck, Danique M H, Schulte, Douwe, Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Völlmy, Franziska, Snijder, Joost, Fortini, Francesca, Papi, Alberto, Volta, Carlo Alberto, Campo, Gianluca, Contoli, Marco, van Gils, Marit J, Spadaro, Savino, Rizzo, Paola, Heck, Albert J R, Biomolecular Mass Spectrometry and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Afd Biomol.Mass Spect. and Proteomics, Bondt, Albert, Hoek, Max, Dingess, Kelly, Tamara, Sem, de Graaf, Bastiaan, Peng, Weiwei, den Boer, Maurits A, Damen, Mirjam, Zwart, Ceri, Barendregt, Arjan, van Rijswijck, Danique M H, Schulte, Douwe, Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Völlmy, Franziska, Snijder, Joost, Fortini, Francesca, Papi, Alberto, Volta, Carlo Alberto, Campo, Gianluca, Contoli, Marco, van Gils, Marit J, Spadaro, Savino, Rizzo, Paola, and Heck, Albert J R
- Published
- 2024
13. Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls.
- Author
-
Verburgh, Myrthe L, Boyd, Anders, Loeff, Maarten F Schim van der, Bakker, Margreet, Wit, Ferdinand W N M, van der Valk, Marc, Grobben, Marloes, Pul, Lisa van, Tejjani, Khadija, Rijswijk, Jacqueline van, Gils, Marit J van, Kootstra, Neeltje A, van der Hoek, Lia, Reiss, Peter, and Study, AGEhIV Cohort
- Subjects
COVID-19 ,SARS-CoV-2 ,SARS-CoV-2 Omicron variant ,HIV infections ,PROPORTIONAL hazards models - Abstract
Background Little is known about the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in people with human immunodeficiency virus (HIV; PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGE
h IV coronavirus disease 2019 substudy participants with well-controlled HIV on antiretroviral therapy and 280 comparable controls, who had received at least the primary vaccination series. Methods From September 2020 onward, participants were assessed every 6 months for the incidence of SARS-CoV-2 infection, per SARS-CoV-2 nucleocapsid antibody assay or self-reported positive antigen or polymerase chain reaction test. Between 1 January and 31 October 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model. Results The cumulative incidence of a first Omicron infection was 58.3% by 31 October 2022, not significantly different between groups. HIV status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-spike immunoglobulin G titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization. Conclusions People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. More booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration. NCT01466582 [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
- Author
-
van Leeuwen, Leanne P. M., Grobben, Marloes, GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L., van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A. S. H.
- Subjects
BOOSTER vaccines ,COVID-19 vaccines ,IMMUNE response ,SARS-CoV-2 Omicron variant ,COMMON variable immunodeficiency - Abstract
Purpose: Previous studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and Tcell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied the immune responses 8 weeks after booster vaccination with mRNA-based COVID-19 vaccines in 171 IEI patients. Moreover, we evaluated the clinical outcomes in these patients one year after the start of the Dutch COVID-19 vaccination campaign. Methods: This study was embedded in a large prospective multicenter study investigating the immunogenicity of COVID-19 mRNA-based vaccines in IEI (VACOPID study). Blood samples were taken from 244 participants 8 weeks after booster vaccination. These participants included 171 IEI patients (X-linked agammaglobulinemia (XLA;N=11), combined immunodeficiency (CID;N=4), common variable immunodeficiency (CVID;N=45), isolated or undefined antibody deficiencies (N=108) and phagocyte defects (N=3)) and 73 controls. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T-cell responses were evaluated. One year after the start of the COVID-19 vaccination program, 334 study participants (239 IEI patients and 95 controls) completed a questionnaire to supplement their clinical data focusing on SARS-CoV-2 infections. Results: After booster vaccination, S-specific IgG titers increased in all COVID-19 naive IEI cohorts and controls, when compared to titers at 6 months after the priming regimen. The fold-increases did not differ between controls and IEI cohorts. SARS-CoV-2-specific T-cell responses also increased equally in all cohorts after booster vaccination compared to 6 months after the priming regimen. Most SARS-CoV-2 infections during the study period occurred in the period when the Omicron variant had become dominant. The clinical course of these infections was mild, although IEI patients experienced more frequent fever and dyspnea compared to controls and their symptoms persisted longer. Conclusion: Our study demonstrates that mRNA-based booster vaccination induces robust recall of memory B-cell and T-cell responses in most IEI patients. One-year clinical follow-up demonstrated that SARS-CoV-2 infections in IEI patients were mild. Given our results, we support booster campaigns with newer variant-specific COVID-19 booster vaccines to IEI patients with milder phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
- Author
-
Brinkkemper, Mitch, Brouwer, Philip J. M., Maisonnasse, Pauline, Grobben, Marloes, Caniels, Tom G., Poniman, Meliawati, Burger, Judith A., Bontjer, Ilja, Oomen, Melissa, Bouhuijs, Joey H., van der Linden, Cynthia A., Villaudy, Julien, van der Velden, Yme U., Sliepen, Kwinten, van Gils, Marit J., Le Grand, Roger, and Sanders, Rogier W.
- Published
- 2021
- Full Text
- View/download PDF
16. The potential of engineered antibodies for HIV-1 therapy and cure
- Author
-
Grobben, Marloes, Stuart, Richard AL, and van Gils, Marit J
- Published
- 2019
- Full Text
- View/download PDF
17. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
- Author
-
van Gils, Marit J., Lavell, Ayesha, van der Straten, Karlijn, Appelman, Brent, Bontjer, Ilja, Poniman, Meliawati, Burger, Judith A., Oomen, Melissa, Bouhuijs, Joey H., van Vught, Lonneke A., Slim, Marleen A., Schinkel, Michiel, Wynberg, Elke, van Willigen, Hugo D. G., Grobben, Marloes, Tejjani, Khadija, van Rijswijk, Jacqueline, Snitselaar, Jonne L., Caniels, Tom G., Vlaar, Alexander P. J., Prins, Maria, de Jong, Menno D., de Bree, Godelieve J., Sikkens, Jonne J., Bomers, Marije K., and Sanders, Rogier W.
- Subjects
Viral antibodies -- Evaluation -- Comparative analysis ,Antibodies -- Evaluation -- Comparative analysis ,Medical personnel -- Health aspects ,Biological sciences - Abstract
Background Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants. Methods and findings In a prospective cohort of 165 SARS-CoV-2 naive health care workers in the Netherlands, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2. Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of mRNA-1273, followed by recipients of BNT162b2 (geometric mean titers (GMT) of 358 [95% CI 231-556] and 214 [95% CI 153-299], respectively; p Conclusions Overall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination, which implies the use of mRNA vaccines for both initial and booster vaccination., Author(s): Marit J. van Gils 1,*, Ayesha Lavell 2, Karlijn van der Straten 1,3, Brent Appelman 4, Ilja Bontjer 1, Meliawati Poniman 1, Judith A. Burger 1, Melissa Oomen 1, [...]
- Published
- 2022
- Full Text
- View/download PDF
18. Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
- Author
-
van Paassen, Pien M., primary, van Pul, Lisa, additional, van der Straten, Karlijn, additional, Buchholtz, Ninée V.J.E., additional, Grobben, Marloes, additional, van Nuenen, Ad C., additional, van Dort, Karel A., additional, Boeser-Nunnink, Brigitte D., additional, van den Essenburg, Mo D., additional, Burger, Judith A., additional, van Luin, Matthijs, additional, Jurriaans, Suzanne, additional, Sanders, Rogier W., additional, Swelsen, Wendy T., additional, Symons, Jori, additional, Klouwens, Michelle J., additional, Nijhuis, Monique, additional, van Gils, Marit J., additional, Prins, Jan M., additional, de Bree, Godelieve J., additional, and Kootstra, Neeltje A., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV
- Author
-
Verburgh, Myrthe L., primary, van Pul, Lisa, additional, Grobben, Marloes, additional, Boyd, Anders, additional, Wit, Ferdinand W. N. M., additional, van Nuenen, Ad C., additional, van Dort, Karel A., additional, Tejjani, Khadija, additional, van Rijswijk, Jacqueline, additional, Bakker, Margreet, additional, van der Hoek, Lia, additional, Schim van der Loeff, Maarten F., additional, van der Valk, Marc, additional, van Gils, Marit J., additional, Kootstra, Neeltje A., additional, Reiss, Peter, additional, Reiss, P., additional, Wit, F. W. N. M., additional, van der Valk, M., additional, Boyd, A., additional, Verburgh, M. L., additional, van der Wulp, I. A. J., additional, Vanbellinghen, M. C., additional, van Eeden, C. J., additional, Schim van der Loeff, M. F., additional, Koole, J. C. D., additional, del Grande, L., additional, Agard, I., additional, Zaheri, S., additional, Hillebregt, M. M. J., additional, Ruijs, Y. M. C., additional, Benschop, D. P., additional, el Berkaoui, A., additional, Kootstra, N. A., additional, Harskamp-Holwerda, A. M., additional, Maurer, I., additional, Mangas Ruiz, M. M., additional, Boeser-Nunnink, B. D. N., additional, Starozhitskaya, O. S., additional, van der Hoek, L., additional, Bakker, M., additional, van Gils, M. J., additional, Dol, L., additional, Rongen, G., additional, Geerlings, S. E., additional, Goorhuis, A., additional, Hovius, J. W. R., additional, Nellen, F. J. B., additional, Prins, J. M., additional, van der Poll, T., additional, Wiersinga, W. J., additional, van Vugt, M., additional, de Bree, G., additional, Lemkes, B. A., additional, Spoorenberg, V., additional, van Eden, J., additional, Pijnappel, F. J. J., additional, Weijsenfeld, A., additional, Smalhout, S., additional, Hylkema-van den Bout, I. J., additional, Bruins, C., additional, Spelbrink, M. E., additional, Postema, P. G., additional, Bisschop, P. H. L. T., additional, Dekker, E., additional, van der Velde, N., additional, Franssen, R., additional, Willemsen, J. M. R., additional, Vogt, L., additional, Portegies, P., additional, Geurtsen, G. J., additional, Visser, I., additional, Schadé, A., additional, Nieuwkerk, P. T., additional, van Steenwijk, R. P., additional, Jonkers, R. E., additional, Majoie, C. B. L. M., additional, Caan, M. W. A., additional, van den Born, B. J. H., additional, Stroes, E. S. G., additional, and van Oorspronk, S., additional
- Published
- 2023
- Full Text
- View/download PDF
20. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity
- Author
-
van Leeuwen, Leanne P M, Grobben, Marloes, GeurtsvanKessel, Corine H, Ellerbroek, Pauline M, de Bree, Godelieve J, Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L, van Gils, Marit J, de Vries, Rory D, Dalm, Virgil A S H, van Leeuwen, Leanne P M, Grobben, Marloes, GeurtsvanKessel, Corine H, Ellerbroek, Pauline M, de Bree, Godelieve J, Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank L, van Gils, Marit J, de Vries, Rory D, and Dalm, Virgil A S H
- Abstract
PURPOSE: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective long-term protection against COVID-19 is therefore of great importance in these patients, but little is known about the decay of the immune response after primary vaccination. We studied the immune responses 6 months after two mRNA-1273 COVID-19 vaccines in 473 IEI patients and subsequently the response to a third mRNA COVID-19 vaccine in 50 patients with common variable immunodeficiency (CVID).METHODS: In a prospective multicenter study, 473 IEI patients (including X-linked agammaglobulinemia (XLA) (N = 18), combined immunodeficiency (CID) (N = 22), CVID (N = 203), isolated or undefined antibody deficiencies (N = 204), and phagocyte defects (N = 16)), and 179 controls were included and followed up to 6 months after two doses of the mRNA-1273 COVID-19 vaccine. Additionally, samples were collected from 50 CVID patients who received a third vaccine 6 months after primary vaccination through the national vaccination program. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T cell responses were assessed.RESULTS: At 6 months after vaccination, the geometric mean antibody titers (GMT) declined in both IEI patients and healthy controls, when compared to GMT 28 days after vaccination. The trajectory of this decline did not differ between controls and most IEI cohorts; however, antibody titers in CID, CVID, and isolated antibody deficiency patients more often dropped to below the responder cut-off compared to controls. Specific T cell responses were still detectable in 77% of controls and 68% of IEI patients at 6 months post vaccination. A third mRNA vaccine resulted in an antibody response in only two out of 30 CVID patients that did not seroconvert after two mRNA vaccines.CONCLUSION: A similar decline in IgG titers and T cell responses was observed in patients with IEI when compared to healthy controls 6
- Published
- 2023
21. Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
- Author
-
MMB Research line 3b, Infection & Immunity, Apotheek Opleiding, MMB Research line 3a, Van Paassen, Pien M., Van Pul, Lisa, Van Der Straten, Karlijn, Buchholtz, Ninée V.J.E., Grobben, Marloes, Van Nuenen, Ad C., Van Dort, Karel A., Boeser-Nunnink, Brigitte D., Van Den Essenburg, Mo D., Burger, Judith A., Van Luin, Matthijs, Jurriaans, Suzanne, Sanders, Rogier W., Swelsen, Wendy T., Symons, Jori, Klouwens, Michelle J., Nijhuis, Monique, Van Gils, Marit J., Prins, Jan M., De Bree, Godelieve J., Kootstra, Neeltje A., MMB Research line 3b, Infection & Immunity, Apotheek Opleiding, MMB Research line 3a, Van Paassen, Pien M., Van Pul, Lisa, Van Der Straten, Karlijn, Buchholtz, Ninée V.J.E., Grobben, Marloes, Van Nuenen, Ad C., Van Dort, Karel A., Boeser-Nunnink, Brigitte D., Van Den Essenburg, Mo D., Burger, Judith A., Van Luin, Matthijs, Jurriaans, Suzanne, Sanders, Rogier W., Swelsen, Wendy T., Symons, Jori, Klouwens, Michelle J., Nijhuis, Monique, Van Gils, Marit J., Prins, Jan M., De Bree, Godelieve J., and Kootstra, Neeltje A.
- Published
- 2023
22. Covid-19 vaccines after 12 weeks of pregnancy helps to protect infants as well as mothers
- Author
-
Zilver, Sanne, primary, van Leeuwen, Liesbeth, additional, de Groot, Christianne J., additional, Grobben, Marloes, additional, Remmelzwaal, Sharon, additional, Burgers, Esmee, additional, van Gils, Marit, additional, van Goudoever, Johannes, additional, Juncker, Hannah, additional, van Keulen, Britt, additional, de Leeuw, Robert, additional, Velasco, Daniela Nunez, additional, and Ris-stalpers, Carrie, additional
- Published
- 2023
- Full Text
- View/download PDF
23. No patient is the same; lessons learned from antibody repertoire profiling in hospitalized severe COVID-19 patients
- Author
-
Bondt, Albert, primary, Hoek, Max, additional, Dingess, Kelly, additional, Tamara, Sem, additional, de Graaf, Bastiaan, additional, Peng, Weiwei, additional, den Boer, Maurits A., additional, Damen, Mirjam, additional, Zwart, Ceri, additional, Barendregt, Arjan, additional, van Rijswijck, Danique M.H., additional, Grobben, Marloes, additional, Tejjani, Khadija, additional, van Rijswijk, Jacqueline, additional, Völlmy, Franziska, additional, Snijder, Joost, additional, Fortini, Francesca, additional, Papi, Alberto, additional, Volta, Carlo Alberto, additional, Campo, Gianluca, additional, Contoli, Marco, additional, van Gils, Marit J., additional, Spadaro, Savino, additional, Rizzo, Paola, additional, and Heck, Albert J.R., additional
- Published
- 2022
- Full Text
- View/download PDF
24. Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
- Author
-
Schriek, Angela I., primary, van Haaren, Marlies M., additional, Poniman, Meliawati, additional, Dekkers, Gillian, additional, Bentlage, Arthur E. H., additional, Grobben, Marloes, additional, Vidarsson, Gestur, additional, Sanders, Rogier W., additional, Verrips, Theo, additional, Geijtenbeek, Teunis B. H., additional, Heukers, Raimond, additional, Kootstra, Neeltje A., additional, de Taeye, Steven W., additional, and van Gils, Marit J., additional
- Published
- 2022
- Full Text
- View/download PDF
25. Differences in systemic and mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children
- Author
-
Keuning, Maya W., primary, Grobben, Marloes, additional, Bijlsma, Merijn W., additional, Anker, Beau, additional, Berman-de Jong, Eveline P., additional, Cohen, Sophie, additional, Felderhof, Mariet, additional, de Groen, Anne-Elise, additional, de Groof, Femke, additional, Rijpert, Maarten, additional, van Eijk, Hetty W. M., additional, Tejjani, Khadija, additional, van Rijswijk, Jacqueline, additional, Steenhuis, Maurice, additional, Rispens, Theo, additional, Plötz, Frans B., additional, van Gils, Marit J., additional, and Pajkrt, Dasja, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Decreased Passive Immunity to Respiratory Viruses through Human Milk during the COVID-19 Pandemic
- Author
-
Grobben, Marloes, primary, Juncker, Hannah G., additional, van der Straten, Karlijn, additional, Lavell, A. H. Ayesha, additional, Schinkel, Michiel, additional, Buis, David T. P., additional, Wilbrink, Maarten F., additional, Tejjani, Khadija, additional, Claireaux, Mathieu A. F., additional, Aartse, Aafke, additional, de Groot, Christianne J. M., additional, Pajkrt, Dasja, additional, Bomers, Marije K., additional, Sikkens, Jonne J., additional, van Gils, Marit J., additional, van Goudoever, Johannes B., additional, and van Keulen, Britt J., additional
- Published
- 2022
- Full Text
- View/download PDF
27. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
- Author
-
Schriek, Angela I, van Haaren, Marlies M, Poniman, Meliawati, Dekkers, Gillian, Bentlage, Arthur E H, Grobben, Marloes, Vidarsson, Gestur, Sanders, Rogier W, Verrips, Theo, Geijtenbeek, Teunis B H, Heukers, Raimond, Kootstra, Neeltje A, de Taeye, Steven W, van Gils, Marit J, Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Experimental Immunology, Graduate School, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Infectious diseases, APH - Aging & Later Life, and Molecular cell biology and Immunology
- Subjects
Fc fusion ,Fc-mediated effector functions ,Immunology ,Single-Domain Antibodies ,neutralization ,HIV Antibodies ,Antibodies, Neutralizing/pharmacology ,Antibodies, Neutralizing ,Antibodies ,nanobodies ,Immunoglobulin G ,HIV Seropositivity ,HIV-1 ,Humans ,Immunology and Allergy ,Neutralizing/pharmacology ,Broadly Neutralizing Antibodies ,Single-Domain Antibodies/pharmacology - Abstract
The most effective treatment for HIV-1, antiretroviral therapy, suppresses viral replication and averts the disease from progression. Nonetheless, there is a need for alternative treatments as it requires daily administration with the possibility of side effects and occurrence of drug resistance. Broadly neutralizing antibodies or nanobodies targeting the HIV-1 envelope glycoprotein are explored as alternative treatment, since they mediate viral suppression and contribute to the elimination of virus-infected cells. Besides neutralization potency and breadth, Fc-mediated effector functions of bNAbs also contribute to thein vivoefficacy. In this study multivalent J3, 2E7 and 1F10 anti-HIV-1 broadly neutralizing nanobodies were generated to improve neutralization potency and IgG1 Fc fusion was utilized to gain Fc-mediated effector functions. Bivalent and trivalent nanobodies, coupled using long glycine-serine linkers, showed increased binding to the HIV-1 Env and enhanced neutralization potency compared to the monovalent variant. Fusion of an IgG1 Fc domain to J3 improved neutralization potency compared to the J3-bihead and restored Fc-mediated effector functions such as antibody-dependent cellular phagocytosis and trogocytosis, and natural killer cell activation. Due to their neutralization breadth and potency and their ability to induce effector functions these nanobody-IgG1 constructs may prove to be valuable towards alternative HIV-1 therapies.
- Published
- 2022
28. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
van Leeuwen, Leanne P.M., primary, GeurtsvanKessel, Corine H., additional, Ellerbroek, Pauline M., additional, de Bree, Godelieve J., additional, Potjewijd, Judith, additional, Rutgers, Abraham, additional, Jolink, Hetty, additional, van de Veerdonk, Frank, additional, van Gorp, Eric C.M., additional, de Wilt, Faye, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Geers, Daryl, additional, Bruns, Anke H.W., additional, Leavis, Helen L., additional, van Haga, Jelle W., additional, Lemkes, Bregtje A., additional, van der Veen, Annelou, additional, de Kruijf-Bazen, S.F.J., additional, van Paassen, Pieter, additional, de Leeuw, Karina, additional, van de Ven, Annick A.J.M., additional, Verbeek-Menken, Petra H., additional, van Wengen, Annelies, additional, Arend, Sandra M., additional, Ruten-Budde, Anja J., additional, van der Ent, Marianne W., additional, van Hagen, P. Martin, additional, Sanders, Rogier W., additional, Grobben, Marloes, additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Nierkens, Stefan, additional, van Gils, Marit J., additional, de Vries, Rory D., additional, and Dalm, Virgil A.S.H., additional
- Published
- 2022
- Full Text
- View/download PDF
29. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
- Author
-
Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Schriek, Angela I, van Haaren, Marlies M, Poniman, Meliawati, Dekkers, Gillian, Bentlage, Arthur E H, Grobben, Marloes, Vidarsson, Gestur, Sanders, Rogier W, Verrips, Theo, Geijtenbeek, Teunis B H, Heukers, Raimond, Kootstra, Neeltje A, de Taeye, Steven W, van Gils, Marit J, Afd Biomol.Mass Spect. and Proteomics, Sub Cell Biology, Biomolecular Mass Spectrometry and Proteomics, Schriek, Angela I, van Haaren, Marlies M, Poniman, Meliawati, Dekkers, Gillian, Bentlage, Arthur E H, Grobben, Marloes, Vidarsson, Gestur, Sanders, Rogier W, Verrips, Theo, Geijtenbeek, Teunis B H, Heukers, Raimond, Kootstra, Neeltje A, de Taeye, Steven W, and van Gils, Marit J
- Published
- 2022
30. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., Dalm, Virgil A.S.H., van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A.S.H.
- Abstract
Background: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients. Objectives: We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI. Methods: In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2–specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination. Results: Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response. Conclusions: COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assess
- Published
- 2022
31. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
KTO Office, MS Interne Geneeskunde, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, CTI, CDL Patiëntenzorg MI, CTI Research, Cancer, van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., Dalm, Virgil A.S.H., KTO Office, MS Interne Geneeskunde, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, CTI, CDL Patiëntenzorg MI, CTI Research, Cancer, van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A.S.H.
- Published
- 2022
32. Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections
- Author
-
Sechan, Ferdyansyah, primary, Grobben, Marloes, additional, Edridge, Arthur W. D., additional, Jebbink, Maarten F., additional, Loens, Katherine, additional, Ieven, Margareta, additional, Goossens, Herman, additional, van Hemert-Glaubitz, Susan, additional, van Gils, Marit J., additional, and van der Hoek, Lia, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Patients With Inborn Errors of Immunity
- Author
-
van Leeuwen, Leanne, primary, GeurtsvanKessel, Corine, additional, Ellerbroek, Pauline, additional, de Bree, Godelieve J., additional, Potjewijd, Judith, additional, Rutgers, Abraham, additional, Jolink, Hetty, additional, van de Veerdonk, Frank L., additional, van Gorp, Eric, additional, de Wilt, Faye, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Geers, Daryl, additional, Bruns, Anke, additional, Leavis, Helen, additional, van Haga, Jelle, additional, Lemkes, Bregtje, additional, van Veen, Annelou, additional, de Kruijff, Suzanne, additional, van Paassen, Pieter, additional, de Leeuw, Karina, additional, van der Ven, Annick, additional, Verbeek, Petra, additional, van Wengen, Annelies, additional, Arend, Sandra, additional, Ruten-Budde, Anja, additional, van der Ent, Marianne, additional, van Hagen, Martin, additional, Sanders, Rogier, additional, Grobben, Marloes, additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, van Gils, Marit J., additional, de Vries, Rory, additional, and Dalm, Virgil, additional
- Published
- 2022
- Full Text
- View/download PDF
34. A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike
- Author
-
Claireaux, Mathieu, primary, Caniels, Tom G, additional, de Gast, Marlon, additional, Han, Julianna, additional, Guerra, Denise, additional, Kerster, Gius, additional, van Schaik, Barbera DC, additional, Jongejan, Aldo, additional, Schriek, Angela I., additional, Grobben, Marloes, additional, Brouwer, Philip JM, additional, van der Straten, Karlijn, additional, Aldon, Yoann, additional, Capella-Pujol, Joan, additional, Snitselaar, Jonne L, additional, Olijhoek, Wouter, additional, Aartse, Aafke, additional, Brinkkemper, Mitch, additional, Bontjer, Ilja, additional, Burger, Judith A, additional, Poniman, Meliawati, additional, Bijl, Tom PL, additional, Torres, Jonathan L, additional, Copps, Jeffrey, additional, Martin, Isabel Cuella, additional, de Taeye, Steven W, additional, de Bree, Godelieve J, additional, Ward, Andrew B, additional, Sliepen, Kwinten, additional, van Kampen, Antoine HC, additional, Moerland, Perry D, additional, Sanders, Rogier W, additional, and van Gils, Marit J, additional
- Published
- 2021
- Full Text
- View/download PDF
35. Saliva SARS-CoV-2 Antibody Prevalence in Children
- Author
-
Keuning, Maya W., primary, Grobben, Marloes, additional, de Groen, Anne-Elise C., additional, Berman-de Jong, Eveline P., additional, Bijlsma, Merijn W., additional, Cohen, Sophie, additional, Felderhof, Mariet, additional, de Groof, Femke, additional, Molanus, Daniel, additional, Oeij, Nadia, additional, Rijpert, Maarten, additional, van Eijk, Hetty W. M., additional, Koen, Gerrit, additional, van der Straten, Karlijn, additional, Oomen, Melissa, additional, Visser, Remco, additional, Linty, Federica, additional, Steenhuis, Maurice, additional, Vidarsson, Gestur, additional, Rispens, Theo, additional, Plötz, Frans B., additional, van Gils, Marit J., additional, and Pajkrt, Dasja, additional
- Published
- 2021
- Full Text
- View/download PDF
36. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
- Author
-
Grobben, Marloes, primary, van der Straten, Karlijn, additional, Brouwer, Philip J.M., additional, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Oomen, Melissa, additional, Eggink, Dirk, additional, Bijl, Tom P.L., additional, van Willigen, Hugo D.G., additional, Wynberg, Elke, additional, Verkaik, Bas J., additional, Figaroa, Orlane J.A., additional, de Vries, Peter J., additional, Boertien, Tessel M., additional, Grand, Roger Le, additional, de Jong, Menno D., additional, Prins, Maria, additional, Chung, Amy W., additional, de Bree, Godelieve J., additional, Sanders, Rogier W., additional, and van Gils, Marit J., additional
- Published
- 2021
- Full Text
- View/download PDF
37. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J.M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Grobben, Marloes, Claireaux, Mathieu, de Gast, Marlon, Marlin, Romain, Chesnais, Virginie, Diry, Ségolène, Allen, Joel D., Watanabe, Yasunori, Giezen, Julia M., Kerster, Gius, Turner, Hannah L., van der Straten, Karlijn, van der Linden, Cynthia A., Aldon, Yoann, Naninck, Thibaut, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Mykytyn, Anna Z., Okba, Nisreen M.A., Schermer, Edith E., van Breemen, Marielle J., Ravichandran, Rashmi, Caniels, Tom G., van Schooten, Jelle, Kahlaoui, Nidhal, Contreras, Vanessa, Lemaître, Julien, Chapon, Catherine, Fang, Raphaël Ho Tsong, Villaudy, Julien, Sliepen, Kwinten, van der Velden, Yme U., Haagmans, Bart L., de Bree, Godelieve J., Ginoux, Eric, Ward, Andrew B., Crispin, Max, King, Neil P., van der Werf, Sylvie, van Gils, Marit J., Le Grand, Roger, Sanders, Rogier W., Brouwer, Philip J.M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Grobben, Marloes, Claireaux, Mathieu, de Gast, Marlon, Marlin, Romain, Chesnais, Virginie, Diry, Ségolène, Allen, Joel D., Watanabe, Yasunori, Giezen, Julia M., Kerster, Gius, Turner, Hannah L., van der Straten, Karlijn, van der Linden, Cynthia A., Aldon, Yoann, Naninck, Thibaut, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Mykytyn, Anna Z., Okba, Nisreen M.A., Schermer, Edith E., van Breemen, Marielle J., Ravichandran, Rashmi, Caniels, Tom G., van Schooten, Jelle, Kahlaoui, Nidhal, Contreras, Vanessa, Lemaître, Julien, Chapon, Catherine, Fang, Raphaël Ho Tsong, Villaudy, Julien, Sliepen, Kwinten, van der Velden, Yme U., Haagmans, Bart L., de Bree, Godelieve J., Ginoux, Eric, Ward, Andrew B., Crispin, Max, King, Neil P., van der Werf, Sylvie, van Gils, Marit J., Le Grand, Roger, and Sanders, Rogier W.
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic. Brouwer et al. present preclinical evidence in support of a COVID-19 vaccine candidate, designed as a self-assembling two-component protein nanoparticle displaying multiple copies of the SARS-CoV-2 spike protein, which induces strong neutralizing antibody responses and protects from high-dose SARS-CoV-2 challenge.
- Published
- 2021
38. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J.M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M.A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Fang, Raphaël Ho Tsong, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Le Grand, Roger, additional, and Sanders, Rogier W., additional
- Published
- 2021
- Full Text
- View/download PDF
39. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J. M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M. A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Ho Tsong Fang, Raphaël, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Grand, Roger Le, additional, and Sanders, Rogier W., additional
- Published
- 2020
- Full Text
- View/download PDF
40. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
- Author
-
Grobben, Marloes, van der Straten, Karlijn, Brouwer, Philip J. M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Appelman, Brent, Lavell, A. H. Ayesha, van Vught, Lonneke A., Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Eggink, Dirk, Bijl, Tom P. L., van Willigen, Hugo D. G., Wynberg, Elke, Verkaik, Bas J., Figaroa, Orlane J. A., de Vries, Peter J., and Boertien, Tessel M.
- Subjects
- *
SARS-CoV-2 , *CONVALESCENT plasma , *COVID-19 pandemic , *COVID-19 , *IMMUNOGLOBULINS - Abstract
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV- 2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV- 2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Distinct groups of autoantigens as drivers of ocular adnexal MALT lymphoma pathogenesis.
- Author
-
Bende RJ, Donner N, Wormhoudt TA, Beentjes A, Scantlebery A, Grobben M, Tejjani K, Chandler F, Sikkema RS, Langerak AW, Guikema JE, and van Noesel CJ
- Subjects
- Humans, Female, Middle Aged, Receptors, Antigen, B-Cell metabolism, Receptors, Antigen, B-Cell immunology, Receptors, Antigen, B-Cell genetics, B-Lymphocytes immunology, B-Lymphocytes metabolism, Male, Aged, Immunoglobulin Variable Region genetics, Immunoglobulin Variable Region immunology, Aged, 80 and over, Epitopes immunology, Adult, Rheumatoid Factor immunology, Lymphoma, B-Cell, Marginal Zone immunology, Lymphoma, B-Cell, Marginal Zone genetics, Autoantigens immunology, Immunoglobulin M immunology, Immunoglobulin M metabolism, Eye Neoplasms immunology, Eye Neoplasms genetics
- Abstract
Chronic B-cell receptor signals incited by cognate antigens are believed to play a crucial role in the pathogenesis of mucosa-associated lymphoid tissue lymphomas. We have explored the immunoglobulin variable regions (IGHV) expressed by 124 ocular adnexal MALT lymphomas (OAML) and tested the in vitro reactivity of recombinant IgM derived from 23 OAMLs. Six of 124 OAMLs (5%) were found to express a high-affinity stereotyped rheumatoid factor. OAMLs have a biased IGHV4-34 usage, which confers intrinsic super auto-antigen reactivity with poly-N-acetyllactosamine (NAL) epitopes, present on cell surface glycoproteins of erythrocytes and B cells. Twenty-one OAMLs (17%) expressed IGHV4-34-encoded B-cell receptors. Five of the 23 recombinant OAML IgMs expressed IGHV4-34, four of which bound to the linear NAL i epitope expressed on B cells but not to the branched NAL I epitope on erythrocytes. One non-IGHV4-34-encoded OAML IgM was also reactive with B cells. Interestingly, three of the 23 OAML IgMs (13%) specifically reacted with proteins of U1-/U-snRNP complexes, which have been implicated as cognate-antigens in various autoimmune diseases such as systemic lupus erythematosus and mixed connective tissue disease. The findings indicate that local autoimmune reactions are instrumental in the pathogenesis of a substantial fraction of OAMLs., (© 2024 Bende et al.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.